Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a mild brain zap boost learning in kids with autism?

NCT ID NCT07092280

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a safe, low-level brain stimulation technique called tDCS can help children with autism who are not making enough progress in their learning programs. The study will involve 24 children aged 5 to 12 who are already in behavioral therapy. They will receive tDCS alongside their usual therapy to see if it improves thinking skills and reduces autism symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and females between 5 and 12 years with autism 2. Enrolled in an ABA program (school or in-home) supervised by a Board Certified Behavior Analyst (BCBA) 3. Stable medical and behavioral treatments for at least 4 weeks prior to, and during the study 4. Able to tolerate wearing tDCS as determined during a week-long daily desensitization training. Exclusion Criteria: 1. Any implanted metal device (heart pacemaker, cochlear implant, surgical clips, etc.) 2. Severe neurological disorders such as TBI, brain tumor, intracranial infection 3. Seizure disorder with a seizure within the last two years 4. Skull defect 5. Peripheral blindness or deafness 6. Medication that might affect tDCS: There have been a few studies concerning the effect of various medications on tDCS. Some may block and others may enhance the effects depending on many factors. The assay used to test these medications was its effect on the motor cortex after stimulation and this may not apply to our montages, however, in order to minimize the chances of having medication affect our results, participants taking the following medications will be excluded: * Na or Ca channel blockers which will include all anti-seizure medications * Medications that affect the NMDA receptors including dextromethorphan, cycloserine * Serotonin reuptake inhibitors * Dopamine stimulating or blocking medications including pergolide, bromocriptine and all antipsychotic medications * Norepinephrine stimulating or blocking agents including propranolol and the stimulants * Drugs that can lower seizure threshold \[imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, phencyclidine, ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline\] * Barbiturates, benzodiazepines, meprobamate, chloral hydrate in the past 4 weeks 7. Acute skin disease 8. History of magnetic or electrical stimulation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • New York State Institute for Basic Research

    RECRUITING

    Staten Island, New York, 10314, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.